GeoMx® Cancer Transcriptome Atlas


Helping Your Research

The GeoMx® Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of tumor biology, the tumor microenvironment, and the immune response. Profile RNA expression of over 1,800 genes simultaneously with spatial resolution from distinct regions of interest with a single tissue section using the GeoMx Digital Spatial Profiler. 

The GeoMx CTA is designed to profile all aspects of tumor and tumor microenvironment biology

  • Profile the global immune response
  • Assess microenvironment immune activity
  • Quantify tumor reactivity to the immune response and therapeutic treatments
  • Measure clinically-derived gene sets including the 18-gene Tumor Inflammation Signature (TIS) known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade, and the 50-gene Prediction Analysis of Microarray 50 signature (PAM50) known to be associated with breast cancer metastasis.

How it Works

The Cancer Transcriptome Atlas (CTA) spatially profiles targets critical to oncology and immuno-oncology research on the GeoMx Digital Spatial Profiler.


Comprehensive RNA content designed for cancer biology research in any tissue sample

  • Coverage of the immune response, tissue microenvironment, tumor biology, and genes from clinically relevant genes sets such as the Tumor Inflammation Signature and PAM50 
  • Analysis of over 100 pathways to explore tumor biology

Compatible with RNAscope® and antibody morphology markers for tissue imaging


Customizable with up to 60 additional targets of interest


For use with next-generation sequencer (NGS) readout and compatible with DSP Data Center

In The Lab

Cancer Transcriptome Atlas
with NGS Readout. The essential tool for spatial genomics in oncology

Read More
Cancer cell

Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response.

The addition of HER2-targeted agents to neoadjuvant chemotherapy has dramatically improved pathological complete response (pCR) rates in early-stage, HER2-positive breast cancer. Nonetheless, up to 50% of patients have residual disease after treatment, while others are likely overtreated.

Next-Generation Digital Histopathology of the Tumor Microenvironment.

Progress in cancer research is substantially dependent on innovative technologies that permit a concerted analysis of the tumor microenvironment and the cellular phenotypes resulting from somatic mutations and post-translational modifications. In view of a large number of genes, multiplied by differential splicing as well as post-translational protein modifications, the ability to identify and quantify the actual phenotypes of individual cell populations in situ, i.

Applicability of spatial transcriptional profiling to cancer research.

Spatial transcriptional profiling provides gene expression information within the important anatomical context of tissue architecture. This approach is well suited to characterizing solid tumors, which develop within a complex landscape of malignant cells, immune cells, and stroma.

Related Resources

See All Resources
Product Bulletin GeoMx Cancer Transcriptome Atlas (CTA) – Product Bulletin
Tradeshow/Conference 3rd Annual
Spatial Genomics Summit
Whitepaper Introduction to GeoMx Cancer Transcriptome Atlas: Normalization
App Note/Tech Note Tech Note – Combined Workflow of GeoMx® Cancer Transcriptome Atlas and RNAscope™ Assays
Tradeshow/Conference Advancing Science: A Spatial Biology Conference

Product Information

Annotated Pathways
Annotated Pathways

Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us